Mylan said that the company is paying approximately $463 million to Novartis for worldwide rights to TOBI Podhaler tobramycin DPI and TOBI tobramycin inhalation solution. Approximately $240 million of that amount will be paid in 2018.
The company said that its acquisition of the products, which are approved in a number of countries for the treatment of P. aeruginosa lung infections in cystic fibrosis patients, “will further enhance Mylan’s respiratory portfolio in the US, Europe and certain Rest of World markets.”
TOBI inhalation solution was approved by the FDA in 1997, and TOBI Podhaler was approved by the FDA in 2013. In Europe, TOBI Podhaler was approved in 2011 and launched in the UK that same year.
Read the Mylan press release.
